Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema

被引:19
|
作者
Bansal, Pooja [1 ]
Agarwal, Aniruddha [2 ]
Gupta, Vishali [1 ]
Singh, Ramandeep [1 ]
Gupta, Amod [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Adv Eye Ctr, Dept Ophthalmol, Chandigarh 160012, India
[2] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA
关键词
Cystoid macular edema; dexamethasone implant; external limiting membrane; optical coherence tomography; Ozurdex; serous retinal detachment; uveitis; FOVEAL PHOTORECEPTOR LAYER; INNER/OUTER SEGMENT JUNCTION; VISUAL-ACUITY; RESOLUTION; INTEGRITY; ASSOCIATION; THERAPY; IMPACT; EYES;
D O I
10.4103/0301-4738.159870
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To correlate the structural and functional changes following intravitreal injection of dexamethasone 0.7 mg (Ozurdex (R)) implant in patients with recalcitrant uveitic cystoid macular edema (CME). Materials and Methods: In a prospective, interventional, nonrandomized study, 30 eyes (27 patients) with uveitic CME received Ozurdex (R) implant and were followed-up for 24 weeks at periodic intervals to monitor structural alterations seen on spectral domain optical coherence tomography (SD-OCT). The outcome measures included change in central macular thickness (CMT) and best-corrected visual acuity (BCVA) as well as structural alterations seen on OCT such as change in the height of cystoid spaces (CSs) and sub-foveal serous retinal detachment (SSRD). The integrity of external limiting membrane and inner-outer segment junction was assessed at baseline and follow-up visits. Results: Mean age of the patients was 46.09 +/- 15.66 years. The mean CMT decreased by 96 mu m at 1-day, 231.64 mu m at 1-week, 254.21 mu m at 4 weeks and 249.14 mu m at 12 weeks (P < 0.001) compared with baseline. BCVA improved from a baseline mean of 0.62 LogMAR units to 0.49 on day 1 to 0.31 at 24 weeks (P < 0.001). A decrease in the mean height of CS, that is, 133.28 mu m from a baseline of 317.71 mu m was noted on the 1st day (P < 0.001). 4 eyes demonstrated the presence of CS at 4 weeks, 1 eye at 6 weeks and 3 eyes at 12 weeks. At baseline, 16 eyes (53.33%) demonstrated the presence of SSRD. Among these, 11 eyes showed resolution of SSRD on day 1. SSRD resolved in all patients at 4 weeks and was maintained up to 24 weeks. Conclusions: Ozurdex (R) implant improves the visual outcome of patients with recalcitrant uveitic CME. Reversibility of retinal changes may be possible following treatment with dexamethasone implant. Thus final visual outcome may be independent of pretreatment CMT, the height of CS or SSRD.
引用
收藏
页码:416 / 422
页数:7
相关论文
共 50 条
  • [31] Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study
    Fonollosa, Alejandro
    Zarranz-Ventura, Javier
    Valverde, Alicia
    Becerra, Erika
    Bernal-Morales, Carolina
    Pastor-Idoate, Salvador
    Angel Zapata, Miguel
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (11) : 2381 - 2390
  • [32] Dexamethasone intravitreal implant (Ozurdex) in patients with diabetic macular edema: Real life safety and efficacy
    Majstruk, L.
    Qu-Knafo, L.
    Sarda, V
    Fajnkuchen, F.
    Nghiem-Buffet, S.
    Grenet, T.
    Chaine, G.
    Giocanti-Auregan, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2020, 43 (03): : 197 - 204
  • [33] Optical coherence tomography classification of diabetic cystoid macular edema
    Helmy, Yasser M.
    Allah, Heba R. Atta
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 1731 - 1737
  • [34] Tolerability and short-term efficacy of the Ozurdex® dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital
    Bernard, Y.
    Bonnin, N.
    Farguette, F.
    Chiambaretta, F.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2016, 39 (01): : 1 - 4
  • [35] Intravitreal dexamethasone implant in naive and previously treated patients with diabetic macular edema: a retrospective study
    Medina-Baena, Maria
    Cejudo-Corbalan, Olga
    Ignacio Garcia-Pulido, Juan
    Jesus Huertos-Carrillo, Maria
    Girela-Lopez, Eloy
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2020, 13 (10) : 1597 - 1605
  • [36] Intravitreal Dexamethasone Implant in Patients with Persistent Macular Edema of Variable Etiologies
    Sorkin, Nir
    Loewenstein, Anat
    Habot-Wilner, Zohar
    Goldstein, Michaela
    OPHTHALMOLOGICA, 2014, 232 (02) : 83 - 91
  • [37] Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema
    Ciulla, Thomas A.
    Kapik, Barry
    Barakat, Mark R.
    Khurana, Rahul N.
    Quan Dong Nguyen
    Grewal, Dilraj S.
    Albini, Thomas
    Cunningham, Emmett T., Jr.
    Goldstein, Debra A.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 237 : 310 - 324
  • [38] Optical coherence tomography in the diagnosis and follow-up of patients with uveitic macular edema
    Reinthal, EK
    Völker, M
    Freudenthaler, N
    Grüb, M
    Zierhut, M
    Schlote, T
    OPHTHALMOLOGE, 2004, 101 (12): : 1181 - 1188
  • [39] The Effect of Age on Dexamethasone Intravitreal Implant (Ozurdex®) Response in Macular Edema Secondary to Branch Retinal Vein Occlusion
    Altunel, Orhan
    Goktas, Altan
    Duru, Necati
    Ozkose, Ayse
    Arifoglu, Hasan Basri
    Atas, Mustafa
    SEMINARS IN OPHTHALMOLOGY, 2018, 33 (02) : 179 - 184
  • [40] Intravitreal dexamethasone implant for cystoid macular edema and inflammation after scleral buckling
    Bonfiglio, Vincenza
    Fallico, Matteo R.
    Russo, Andrea
    De Grande, Vittorio
    Longo, Antonio
    Uva, Maurizio G.
    Reibaldi, Michele
    Avitabile, Teresio
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2015, 25 (05) : E98 - E100